ATM and breast cancer: Thus, while we cannot exclude that our nonsignificant finding is actually indicative of little or no risk of breast cancer conferred by MRN gene protein-truncating variants, our data are more strongly in accord with the hypothesis that they confer an intermediate risk of magnitude similar to the risk conferred by truncating variants in ATM.